Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 8/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13731100 | 0.90 | PTGS2 (0.48) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13730685 | 0.89 | PTGS2 (0.47) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13730519 | 0.85 | PTGS2 (0.56) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13732187 | 0.84 | PTGS2 (0.44) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL15726409 | 0.83 | PTGS2 (0.58) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL12715087 | 0.83 | PTGS2 (0.58) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL17268521 | 0.82 | PTGS2 (0.58) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13089807 | 0.82 | AKR1C3 (0.43) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL19719468 | 0.81 | PTGS2 (0.60) | PTGS2PTGS1AKR1C3AKR1C2LMNA | |
| SCHEMBL13483546 | 0.78 | AKR1C3 (0.49) | PTGS2PTGS1AKR1C3AKR1C2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8691869-B2 | Pharmaceutical formulation of nitrooxyderivatives of NSAIDs | NICOX S.A. (FR) | 2014-04-08 | — | — | US | disclosed |
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | NICOX SA (FR) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203759-A1 | PHARMACEUTICAL FORMULATION OF NITROOXYDERIVATIVES OF NSAIDS | FASN, PTGS1, NOS2 | PTGS2 5/4885PTGS1 2/4885AKR1C3 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.